Organon & Co. (LON: 0A9W)

Market Cap	3.32B
Revenue (ttm)	4.78B
Net Income (ttm)	970.68M
Shares Out	n/a
EPS (ttm)	3.76
PE Ratio	3.42
Forward PE	n/a
Dividend	0.88 (5.56%)
Ex-Dividend Date	Nov 12, 2024

Volume	598
Average Volume	2,019
Open	15.80
Previous Close	15.86
Day's Range	15.80 - 15.94
52-Week Range	10.86 - 18.17
Beta	n/a
RSI	55.77
Earnings Date	Feb 14, 2025

About Organon & Co.

Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women’s health in the United States and internationally. Its women’s health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple o...

• Industry: Pharmaceutical Preparations
• Founded: 2020
• Employees: 10,000
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0A9W

Financial Performance

In 2023, Organon & Co.'s revenue was $6.26 billion, an increase of 1.44% compared to the previous year's $6.17 billion. Earnings were $1.02 billion, an increase of 11.56%.

Financial numbers in USD